JPH11509193A - 細胞傷害を増強するための細胞周期動力学の動的遅延方法 - Google Patents

細胞傷害を増強するための細胞周期動力学の動的遅延方法

Info

Publication number: JPH11509193A
Authority: JP; Japan
Prior art keywords: cells; cell; target; agent; dthd
Prior art date: 1995-06-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP9504545A

Other languages

English (en)

Japanese (ja)

Inventor

エム．グリムリー，フィリップ

メータ，スニル

Original Assignee

ヘンリーエム．ジャクソンファウンデーションフォーザアドバンスメントオブミリタリーメディシン

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-27

Filing date

1996-06-26

Publication date

1999-08-17

1996-06-26 Application filed by ヘンリーエム．ジャクソンファウンデーションフォーザアドバンスメントオブミリタリーメディシン filed Critical ヘンリーエム．ジャクソンファウンデーションフォーザアドバンスメントオブミリタリーメディシン

1999-08-17 Publication of JPH11509193A publication Critical patent/JPH11509193A/ja

Status Pending legal-status Critical Current

Links

230000022131 cell cycle Effects 0.000 title claims abstract description 156
238000000034 method Methods 0.000 title claims abstract description 126
230000005779 cell damage Effects 0.000 title description 17
208000037887 cell injury Diseases 0.000 title description 16
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims abstract description 190
HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims abstract description 177
CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims abstract description 177
HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims abstract description 175
239000003814 drug Substances 0.000 claims abstract description 173
229940079593 drug Drugs 0.000 claims abstract description 167
239000003795 chemical substances by application Substances 0.000 claims abstract description 56
108010041388 Ribonucleotide Reductases Proteins 0.000 claims abstract description 36
102000000505 Ribonucleotide Reductases Human genes 0.000 claims abstract description 35
231100000433 cytotoxic Toxicity 0.000 claims abstract description 26
229940127089 cytotoxic agent Drugs 0.000 claims abstract description 26
230000001472 cytotoxic effect Effects 0.000 claims abstract description 26
239000002254 cytotoxic agent Substances 0.000 claims abstract description 19
231100000599 cytotoxic agent Toxicity 0.000 claims abstract description 18
ZZWAFVPZTZSAEM-RIGQTMPJSA-N KT 5926 Chemical compound C12=CC=CC=C2C2=C(CNC3=O)C3=C3C4=CC(OCCC)=CC=C4N4C3=C2N1[C@]1(C)[C@@](O)(C(=O)OC)C[C@H]4O1 ZZWAFVPZTZSAEM-RIGQTMPJSA-N 0.000 claims abstract description 12
239000003166 dihydrofolate reductase inhibitor Substances 0.000 claims abstract description 5
229940117937 Dihydrofolate reductase inhibitor Drugs 0.000 claims abstract description 4
229940122149 Thymidylate synthase inhibitor Drugs 0.000 claims abstract description 4
239000003734 thymidylate synthase inhibitor Substances 0.000 claims abstract description 4
229940123934 Reductase inhibitor Drugs 0.000 claims abstract description 3
229940123014 DNA polymerase inhibitor Drugs 0.000 claims abstract 3
206010028980 Neoplasm Diseases 0.000 claims description 97
201000011510 cancer Diseases 0.000 claims description 86
230000018199 S phase Effects 0.000 claims description 63
230000006378 damage Effects 0.000 claims description 58
238000012360 testing method Methods 0.000 claims description 52
230000009036 growth inhibition Effects 0.000 claims description 28
230000008569 process Effects 0.000 claims description 28
239000000126 substance Substances 0.000 claims description 18
230000007704 transition Effects 0.000 claims description 16
208000015181 infectious disease Diseases 0.000 claims description 14
238000010790 dilution Methods 0.000 claims description 12
239000012895 dilution Substances 0.000 claims description 12
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 claims description 9
-1 K252A Chemical compound 0.000 claims description 8
229960000485 methotrexate Drugs 0.000 claims description 7
238000012545 processing Methods 0.000 claims description 7
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical group C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 claims description 6
SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 claims description 6
108010006654 Bleomycin Proteins 0.000 claims description 5
229960001561 bleomycin Drugs 0.000 claims description 5
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical group N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 5
238000011002 quantification Methods 0.000 claims description 5
230000008485 antagonism Effects 0.000 claims description 4
QJTQKPNNQVLHHO-UHFFFAOYSA-N 9h-carbazole;1h-indole Chemical group C1=CC=C2NC=CC2=C1.C1=CC=C2C3=CC=CC=C3NC2=C1 QJTQKPNNQVLHHO-UHFFFAOYSA-N 0.000 claims description 3
208000035473 Communicable disease Diseases 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 2
XLBLMKKJYRLJNT-UHFFFAOYSA-N 1H-pyrimidine-2,4-dione hydrofluoride Chemical group O=C(C=CN1)NC1=O.F XLBLMKKJYRLJNT-UHFFFAOYSA-N 0.000 claims 1
230000004707 G1/S transition Effects 0.000 claims 1
230000003013 cytotoxicity Effects 0.000 abstract description 35
231100000135 cytotoxicity Toxicity 0.000 abstract description 35
238000004458 analytical method Methods 0.000 abstract description 24
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 abstract description 9
KOZFSFOOLUUIGY-SOLYNIJKSA-N K-252a Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@](C(=O)OC)(O)[C@]4(C)O1 KOZFSFOOLUUIGY-SOLYNIJKSA-N 0.000 abstract description 6
239000003909 protein kinase inhibitor Substances 0.000 abstract description 4
239000011885 synergistic combination Substances 0.000 abstract description 4
230000001939 inductive effect Effects 0.000 abstract description 3
229940043355 kinase inhibitor Drugs 0.000 abstract description 3
229940104230 thymidine Drugs 0.000 abstract description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 abstract description 2
239000002547 new drug Substances 0.000 abstract description 2
239000003534 dna topoisomerase inhibitor Substances 0.000 abstract 1
229940044693 topoisomerase inhibitor Drugs 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 447
230000000694 effects Effects 0.000 description 97
108020004414 DNA Proteins 0.000 description 71
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 57
229960001330 hydroxycarbamide Drugs 0.000 description 57
241000282414 Homo sapiens Species 0.000 description 56
238000002512 chemotherapy Methods 0.000 description 48
230000002195 synergetic effect Effects 0.000 description 42
238000011282 treatment Methods 0.000 description 40
230000003211 malignant effect Effects 0.000 description 37
206010025323 Lymphomas Diseases 0.000 description 31
238000000684 flow cytometry Methods 0.000 description 30
230000006907 apoptotic process Effects 0.000 description 28
230000012010 growth Effects 0.000 description 27
230000009471 action Effects 0.000 description 25
230000001965 increasing effect Effects 0.000 description 24
239000003112 inhibitor Substances 0.000 description 21
208000027418 Wounds and injury Diseases 0.000 description 20
208000014674 injury Diseases 0.000 description 20
238000005259 measurement Methods 0.000 description 20
230000025084 cell cycle arrest Effects 0.000 description 19
108090000623 proteins and genes Proteins 0.000 description 19
102000003855 L-lactate dehydrogenase Human genes 0.000 description 18
108700023483 L-lactate dehydrogenases Proteins 0.000 description 18
210000001519 tissue Anatomy 0.000 description 18
101150001544 crr gene Proteins 0.000 description 17
238000000338 in vitro Methods 0.000 description 17
241000699670 Mus sp. Species 0.000 description 16
239000003153 chemical reaction reagent Substances 0.000 description 16
230000006870 function Effects 0.000 description 16
230000003068 static effect Effects 0.000 description 16
238000013467 fragmentation Methods 0.000 description 15
238000006062 fragmentation reaction Methods 0.000 description 15
230000005764 inhibitory process Effects 0.000 description 15
230000003993 interaction Effects 0.000 description 15
210000004206 promonocyte Anatomy 0.000 description 15
230000004543 DNA replication Effects 0.000 description 14
102000004190 Enzymes Human genes 0.000 description 14
108090000790 Enzymes Proteins 0.000 description 14
102000004169 proteins and genes Human genes 0.000 description 14
230000027311 M phase Effects 0.000 description 13
241001465754 Metazoa Species 0.000 description 13
239000002609 medium Substances 0.000 description 13
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 12
230000005778 DNA damage Effects 0.000 description 12
231100000277 DNA damage Toxicity 0.000 description 12
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 12
238000007405 data analysis Methods 0.000 description 12
230000002147 killing effect Effects 0.000 description 12
239000002246 antineoplastic agent Substances 0.000 description 11
229960004316 cisplatin Drugs 0.000 description 11
230000003111 delayed effect Effects 0.000 description 11
239000000047 product Substances 0.000 description 11
230000035755 proliferation Effects 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
239000000523 sample Substances 0.000 description 11
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 10
230000006820 DNA synthesis Effects 0.000 description 10
101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 10
241000699666 Mus <mouse, genus> Species 0.000 description 10
102100038042 Retinoblastoma-associated protein Human genes 0.000 description 10
241000700605 Viruses Species 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
239000008280 blood Substances 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
238000003119 immunoblot Methods 0.000 description 10
230000002503 metabolic effect Effects 0.000 description 10
244000045947 parasite Species 0.000 description 10
230000005855 radiation Effects 0.000 description 10
230000010076 replication Effects 0.000 description 10
239000000758 substrate Substances 0.000 description 10
230000008685 targeting Effects 0.000 description 10
238000003556 assay Methods 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
230000002708 enhancing effect Effects 0.000 description 9
230000002401 inhibitory effect Effects 0.000 description 9
238000000691 measurement method Methods 0.000 description 9
238000006366 phosphorylation reaction Methods 0.000 description 9
238000013207 serial dilution Methods 0.000 description 9
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
231100000002 MTT assay Toxicity 0.000 description 8
238000000134 MTT assay Methods 0.000 description 8
230000002159 abnormal effect Effects 0.000 description 8
238000011161 development Methods 0.000 description 8
230000018109 developmental process Effects 0.000 description 8
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
239000000499 gel Substances 0.000 description 8
238000001502 gel electrophoresis Methods 0.000 description 8
210000005170 neoplastic cell Anatomy 0.000 description 8
230000026731 phosphorylation Effects 0.000 description 8
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 7
108091054455 MAP kinase family Proteins 0.000 description 7
102000043136 MAP kinase family Human genes 0.000 description 7
230000036765 blood level Effects 0.000 description 7
229950004398 broxuridine Drugs 0.000 description 7
230000032823 cell division Effects 0.000 description 7
230000008859 change Effects 0.000 description 7
238000004163 cytometry Methods 0.000 description 7
239000001963 growth medium Substances 0.000 description 7
229920002521 macromolecule Polymers 0.000 description 7
230000004060 metabolic process Effects 0.000 description 7
230000036470 plasma concentration Effects 0.000 description 7
230000002062 proliferating effect Effects 0.000 description 7
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 7
230000035945 sensitivity Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
230000004083 survival effect Effects 0.000 description 7
210000004881 tumor cell Anatomy 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
102000053602 DNA Human genes 0.000 description 6
AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
108091000080 Phosphotransferase Proteins 0.000 description 6
240000004808 Saccharomyces cerevisiae Species 0.000 description 6
230000030833 cell death Effects 0.000 description 6
230000022534 cell killing Effects 0.000 description 6
230000001419 dependent effect Effects 0.000 description 6
231100000673 dose–response relationship Toxicity 0.000 description 6
210000003743 erythrocyte Anatomy 0.000 description 6
230000014509 gene expression Effects 0.000 description 6
230000001738 genotoxic effect Effects 0.000 description 6
238000001802 infusion Methods 0.000 description 6
230000000977 initiatory effect Effects 0.000 description 6
230000033001 locomotion Effects 0.000 description 6
229920000609 methyl cellulose Polymers 0.000 description 6
239000001923 methylcellulose Substances 0.000 description 6
235000010981 methylcellulose Nutrition 0.000 description 6
108020004707 nucleic acids Proteins 0.000 description 6
102000039446 nucleic acids Human genes 0.000 description 6
150000007523 nucleic acids Chemical class 0.000 description 6
102000020233 phosphotransferase Human genes 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
239000007787 solid Substances 0.000 description 6
238000007920 subcutaneous administration Methods 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
241000196324 Embryophyta Species 0.000 description 5
231100000416 LDH assay Toxicity 0.000 description 5
208000030852 Parasitic disease Diseases 0.000 description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
238000002835 absorbance Methods 0.000 description 5
230000035508 accumulation Effects 0.000 description 5
238000009825 accumulation Methods 0.000 description 5
239000003242 anti bacterial agent Substances 0.000 description 5
230000000340 anti-metabolite Effects 0.000 description 5
229940100197 antimetabolite Drugs 0.000 description 5
239000002256 antimetabolite Substances 0.000 description 5
GIXWDMTZECRIJT-UHFFFAOYSA-N aurintricarboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=CC1=C(C=1C=C(C(O)=CC=1)C(O)=O)C1=CC=C(O)C(C(O)=O)=C1 GIXWDMTZECRIJT-UHFFFAOYSA-N 0.000 description 5
230000008901 benefit Effects 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
230000000254 damaging effect Effects 0.000 description 5
230000001934 delay Effects 0.000 description 5
231100000024 genotoxic Toxicity 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
238000011534 incubation Methods 0.000 description 5
238000002843 lactate dehydrogenase assay Methods 0.000 description 5
239000007788 liquid Substances 0.000 description 5
201000004792 malaria Diseases 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
239000000203 mixture Substances 0.000 description 5
230000004899 motility Effects 0.000 description 5
230000035772 mutation Effects 0.000 description 5
230000001613 neoplastic effect Effects 0.000 description 5
210000004940 nucleus Anatomy 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
238000001959 radiotherapy Methods 0.000 description 5
230000002441 reversible effect Effects 0.000 description 5
102220002645 rs104894309 Human genes 0.000 description 5
235000019333 sodium laurylsulphate Nutrition 0.000 description 5
238000010186 staining Methods 0.000 description 5
239000000725 suspension Substances 0.000 description 5
241000282472 Canis lupus familiaris Species 0.000 description 4
102000016736 Cyclin Human genes 0.000 description 4
108050006400 Cyclin Proteins 0.000 description 4
108090000266 Cyclin-dependent kinases Proteins 0.000 description 4
102000003903 Cyclin-dependent kinases Human genes 0.000 description 4
241000282412 Homo Species 0.000 description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
102100038895 Myc proto-oncogene protein Human genes 0.000 description 4
101710135898 Myc proto-oncogene protein Proteins 0.000 description 4
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
108700020796 Oncogene Proteins 0.000 description 4
241000223960 Plasmodium falciparum Species 0.000 description 4
239000012980 RPMI-1640 medium Substances 0.000 description 4
101710150448 Transcriptional regulator Myc Proteins 0.000 description 4
230000003042 antagnostic effect Effects 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
210000000170 cell membrane Anatomy 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
238000004737 colorimetric analysis Methods 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
239000013078 crystal Substances 0.000 description 4
230000002950 deficient Effects 0.000 description 4
238000009826 distribution Methods 0.000 description 4
239000000890 drug combination Substances 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
210000003527 eukaryotic cell Anatomy 0.000 description 4
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
230000006698 induction Effects 0.000 description 4
230000002458 infectious effect Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000011081 inoculation Methods 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
230000007774 longterm Effects 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
150000003230 pyrimidines Chemical class 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000008439 repair process Effects 0.000 description 4
229910052717 sulfur Inorganic materials 0.000 description 4
230000009044 synergistic interaction Effects 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
238000005406 washing Methods 0.000 description 4
OLXZPDWKRNYJJZ-UHFFFAOYSA-N 2'-dA Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(CO)O1 OLXZPDWKRNYJJZ-UHFFFAOYSA-N 0.000 description 3
YKBGVTZYEHREMT-UHFFFAOYSA-N 2'-deoxyguanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 description 3
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
229920001817 Agar Polymers 0.000 description 3
108090001008 Avidin Proteins 0.000 description 3
206010008342 Cervix carcinoma Diseases 0.000 description 3
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 3
102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 3
241000233866 Fungi Species 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 description 3
241000224016 Plasmodium Species 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 description 3
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000008272 agar Substances 0.000 description 3
229940100198 alkylating agent Drugs 0.000 description 3
239000002168 alkylating agent Substances 0.000 description 3
230000001640 apoptogenic effect Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000001516 cell proliferation assay Methods 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
201000010881 cervical cancer Diseases 0.000 description 3
230000005757 colony formation Effects 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
229960000975 daunorubicin Drugs 0.000 description 3
230000034994 death Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
235000013399 edible fruits Nutrition 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
230000007613 environmental effect Effects 0.000 description 3
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
229960005420 etoposide Drugs 0.000 description 3
239000000284 extract Substances 0.000 description 3
230000035558 fertility Effects 0.000 description 3
229960000961 floxuridine Drugs 0.000 description 3
230000002538 fungal effect Effects 0.000 description 3
210000004602 germ cell Anatomy 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
230000002427 irreversible effect Effects 0.000 description 3
238000002372 labelling Methods 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
239000002502 liposome Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
230000009456 molecular mechanism Effects 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
108700025694 p53 Genes Proteins 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
231100000614 poison Toxicity 0.000 description 3
230000000750 progressive effect Effects 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
239000004576 sand Substances 0.000 description 3
238000000926 separation method Methods 0.000 description 3
230000001568 sexual effect Effects 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000000153 supplemental effect Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
239000003440 toxic substance Substances 0.000 description 3
238000001890 transfection Methods 0.000 description 3
238000012546 transfer Methods 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
238000002054 transplantation Methods 0.000 description 3
241001529453 unidentified herpesvirus Species 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
IOVLYTLORVHIGG-UHFFFAOYSA-N 1-(4-nitrophenyl)-5-phenyl-1h-tetrazol-1-ium;chloride Chemical compound [Cl-].C1=CC([N+](=O)[O-])=CC=C1[N+]1=C(C=2C=CC=CC=2)N=NN1 IOVLYTLORVHIGG-UHFFFAOYSA-N 0.000 description 2
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
101150012716 CDK1 gene Proteins 0.000 description 2
108091007914 CDKs Proteins 0.000 description 2
208000005623 Carcinogenesis Diseases 0.000 description 2
206010007269 Carcinogenicity Diseases 0.000 description 2
238000007400 DNA extraction Methods 0.000 description 2
230000033616 DNA repair Effects 0.000 description 2
241000450599 DNA viruses Species 0.000 description 2
101100226058 Dictyostelium discoideum erkB gene Proteins 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 2
102100031780 Endonuclease Human genes 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
241000206602 Eukaryota Species 0.000 description 2
206010017533 Fungal infection Diseases 0.000 description 2
102100039869 Histone H2B type F-S Human genes 0.000 description 2
101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
241000204031 Mycoplasma Species 0.000 description 2
BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 2
208000009182 Parasitemia Diseases 0.000 description 2
206010035500 Plasmodium falciparum infection Diseases 0.000 description 2
229940123066 Polymerase inhibitor Drugs 0.000 description 2
102000029797 Prion Human genes 0.000 description 2
108091000054 Prion Proteins 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
108020004440 Thymidine kinase Proteins 0.000 description 2
239000007984 Tris EDTA buffer Substances 0.000 description 2
101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
238000011226 adjuvant chemotherapy Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 2
238000011717 athymic nude mouse Methods 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000003851 biochemical process Effects 0.000 description 2
239000003139 biocide Substances 0.000 description 2
239000006177 biological buffer Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000031018 biological processes and functions Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
229960001948 caffeine Drugs 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
230000036952 cancer formation Effects 0.000 description 2
230000005907 cancer growth Effects 0.000 description 2
231100000504 carcinogenesis Toxicity 0.000 description 2
231100000260 carcinogenicity Toxicity 0.000 description 2
230000007670 carcinogenicity Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000010370 cell cloning Methods 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000006369 cell cycle progression Effects 0.000 description 2
230000007248 cellular mechanism Effects 0.000 description 2
210000001175 cerebrospinal fluid Anatomy 0.000 description 2
230000000973 chemotherapeutic effect Effects 0.000 description 2
229940044683 chemotherapy drug Drugs 0.000 description 2
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
229960003677 chloroquine Drugs 0.000 description 2
238000009096 combination chemotherapy Methods 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
230000021953 cytokinesis Effects 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
238000006209 dephosphorylation reaction Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
229960001673 diethyltoluamide Drugs 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000011049 filling Methods 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
239000004009 herbicide Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
210000002865 immune cell Anatomy 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000006882 induction of apoptosis Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
230000003902 lesion Effects 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
239000003094 microcapsule Substances 0.000 description 2
238000013508 migration Methods 0.000 description 2
229960004857 mitomycin Drugs 0.000 description 2
230000011278 mitosis Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000036457 multidrug resistance Effects 0.000 description 2
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
230000036515 potency Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
230000008261 resistance mechanism Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
210000001082 somatic cell Anatomy 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
230000009897 systematic effect Effects 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
229940126585 therapeutic drug Drugs 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000005740 tumor formation Effects 0.000 description 2
230000035899 viability Effects 0.000 description 2
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
KAWIOCMUARENDQ-UHFFFAOYSA-N 2-(4-chlorophenyl)sulfanyl-n-(4-pyridin-2-yl-1,3-thiazol-2-yl)acetamide Chemical compound C1=CC(Cl)=CC=C1SCC(=O)NC1=NC(C=2N=CC=CC=2)=CS1 KAWIOCMUARENDQ-UHFFFAOYSA-N 0.000 description 1
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
108091007065 BIRCs Proteins 0.000 description 1
235000018185 Betula X alpestris Nutrition 0.000 description 1
235000018212 Betula X uliginosa Nutrition 0.000 description 1
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
102100024829 DNA polymerase delta catalytic subunit Human genes 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
231100001074 DNA strand break Toxicity 0.000 description 1
CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
206010048768 Dermatosis Diseases 0.000 description 1
101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
102100022404 E3 ubiquitin-protein ligase Midline-1 Human genes 0.000 description 1
101710102210 E3 ubiquitin-protein ligase Midline-1 Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
208000002476 Falciparum Malaria Diseases 0.000 description 1
229940123414 Folate antagonist Drugs 0.000 description 1
206010064571 Gene mutation Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
206010053759 Growth retardation Diseases 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 description 1
101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 description 1
101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
102000047918 Myelin Basic Human genes 0.000 description 1
101710107068 Myelin basic protein Proteins 0.000 description 1
BWJJSYVJOLHQFF-AMLDTQNSSA-N N'-(4-iodoanilino)-N-(4-nitrophenyl)iminobenzenecarboximidamide Chemical compound C1=CC=C(C=C1)/C(=N/NC2=CC=C(C=C2)I)/N=NC3=CC=C(C=C3)[N+](=O)[O-] BWJJSYVJOLHQFF-AMLDTQNSSA-N 0.000 description 1
102000011931 Nucleoproteins Human genes 0.000 description 1
108010061100 Nucleoproteins Proteins 0.000 description 1
108010047956 Nucleosomes Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
208000012868 Overgrowth Diseases 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108700020978 Proto-Oncogene Proteins 0.000 description 1
102000052575 Proto-Oncogene Human genes 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
108700005075 Regulator Genes Proteins 0.000 description 1
HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
241000606701 Rickettsia Species 0.000 description 1
239000012722 SDS sample buffer Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
102000005497 Thymidylate Synthase Human genes 0.000 description 1
241001265087 Trichys Species 0.000 description 1
MSLJYSGFUMYUDX-UHFFFAOYSA-N Trimidox Chemical compound ON=C(N)C1=CC(O)=C(O)C(O)=C1 MSLJYSGFUMYUDX-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
241001454727 Xenos Species 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
229960004176 aclarubicin Drugs 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
230000000078 anti-malarial effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
238000011203 antimicrobial therapy Methods 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000005250 beta ray Effects 0.000 description 1
230000008238 biochemical pathway Effects 0.000 description 1
238000005842 biochemical reaction Methods 0.000 description 1
230000004791 biological behavior Effects 0.000 description 1
230000009141 biological interaction Effects 0.000 description 1
238000011237 bivariate analysis Methods 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
229960005520 bryostatin Drugs 0.000 description 1
MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007978 cacodylate buffer Substances 0.000 description 1
229940127093 camptothecin Drugs 0.000 description 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
230000005880 cancer cell killing Effects 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
230000012820 cell cycle checkpoint Effects 0.000 description 1
230000009743 cell cycle entry Effects 0.000 description 1
230000033366 cell cycle process Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000009087 cell motility Effects 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
CETPSERCERDGAM-UHFFFAOYSA-N ceric oxide Chemical compound O=[Ce]=O CETPSERCERDGAM-UHFFFAOYSA-N 0.000 description 1
229910000422 cerium(IV) oxide Inorganic materials 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000035572 chemosensitivity Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
210000003040 circulating cell Anatomy 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
231100000096 clonogenic assay Toxicity 0.000 description 1
238000009643 clonogenic assay Methods 0.000 description 1
230000035602 clotting Effects 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
238000011254 conventional chemotherapy Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
230000003831 deregulation Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
230000000431 effect on proliferation Effects 0.000 description 1
150000002085 enols Chemical class 0.000 description 1
230000006353 environmental stress Effects 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
210000001339 epidermal cell Anatomy 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
230000008029 eradication Effects 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
238000009093 first-line therapy Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
239000004052 folic acid antagonist Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000012224 gene deletion Methods 0.000 description 1
238000012637 gene transfection Methods 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
238000007429 general method Methods 0.000 description 1
231100000025 genetic toxicology Toxicity 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
230000009422 growth inhibiting effect Effects 0.000 description 1
239000003966 growth inhibitor Substances 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
239000000383 hazardous chemical Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000003284 homeostatic effect Effects 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
238000005286 illumination Methods 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000008076 immune mechanism Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
239000000077 insect repellent Substances 0.000 description 1
239000002917 insecticide Substances 0.000 description 1
230000007154 intracellular accumulation Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
210000005128 keratinized epithelium Anatomy 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
244000144972 livestock Species 0.000 description 1
239000012160 loading buffer Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
238000002796 luminescence method Methods 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000021121 meiosis Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
238000013048 microbiological method Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000013206 minimal dilution Methods 0.000 description 1
231100000324 minimal toxicity Toxicity 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004001 molecular interaction Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
230000007886 mutagenicity Effects 0.000 description 1
231100000299 mutagenicity Toxicity 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
230000009707 neogenesis Effects 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
210000001623 nucleosome Anatomy 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000036281 parasite infection Effects 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
238000012342 propidium iodide staining Methods 0.000 description 1
238000011471 prostatectomy Methods 0.000 description 1
230000004224 protection Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000009979 protective mechanism Effects 0.000 description 1
108010005709 protein kinase C kinase Proteins 0.000 description 1
230000001185 psoriatic effect Effects 0.000 description 1
230000005180 public health Effects 0.000 description 1
239000002213 purine nucleotide Substances 0.000 description 1
239000002719 pyrimidine nucleotide Substances 0.000 description 1
238000012207 quantitative assay Methods 0.000 description 1
229960001285 quercetin Drugs 0.000 description 1
235000005875 quercetin Nutrition 0.000 description 1
230000000191 radiation effect Effects 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000022983 regulation of cell cycle Effects 0.000 description 1
230000003716 rejuvenation Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
108010060028 replitase Proteins 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000000452 restraining effect Effects 0.000 description 1
201000006845 reticulosarcoma Diseases 0.000 description 1
208000029922 reticulum cell sarcoma Diseases 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
210000001563 schizont Anatomy 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
241000894007 species Species 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
238000010998 test method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
230000008467 tissue growth Effects 0.000 description 1
230000007838 tissue remodeling Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
108091006106 transcriptional activators Proteins 0.000 description 1
238000005820 transferase reaction Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
230000005909 tumor killing Effects 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

JP9504545A 1995-06-27 1996-06-26 細胞傷害を増強するための細胞周期動力学の動的遅延方法 Pending JPH11509193A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US54695P	1995-06-27	1995-06-27
US60/000,546		1995-06-27
US66893296A	1996-06-24	1996-06-24
US08/668,932		1996-06-24
PCT/US1996/010921 WO1997001344A2 (fr)	1995-06-27	1996-06-26	Procede de ralentissement dynamique de la cinetique du cycle cellulaire, destine a potentialiser les lesions cellulaires

Publications (1)

Publication Number	Publication Date
JPH11509193A true JPH11509193A (ja)	1999-08-17

Family

ID=26667798

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP9504545A Pending JPH11509193A (ja)	1995-06-27	1996-06-26	細胞傷害を増強するための細胞周期動力学の動的遅延方法

Country Status (5)

Country	Link
EP (1)	EP0835111A2 (fr)
JP (1)	JPH11509193A (fr)
AU (1)	AU715527B2 (fr)
CA (1)	CA2225682A1 (fr)
WO (1)	WO1997001344A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2010510222A (ja) *	2006-11-17	2010-04-02	シェーリングコーポレイション	増殖性障害に対する併用療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4448534A (en) *	1978-03-30	1984-05-15	American Hospital Corporation	Antibiotic susceptibility testing
US5166140A (en) *	1987-05-05	1992-11-24	City Of Hope	Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
DE3827974A1 (de) *	1988-08-18	1990-02-22	Boehringer Mannheim Gmbh	Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
WO1992019765A1 (fr) *	1991-05-08	1992-11-12	The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Procede de conception de traitements du cancer, procedes et compositions pharmaceutiques de traitements du cancer
IE921315A1 (en) *	1991-07-03	1993-01-13	Regeneron Pharma	Method and assay system for neurothrophin activity
ATE247471T1 (de) *	1991-11-15	2003-09-15	Smithkline Beecham Corp	Cisplatin und topotecan enthaltende zusammensetzung als antitumor.
CA2140653A1 (fr) *	1992-08-12	1994-03-03	Irene Abraham	Inhibiteurs de la proteine kinase et composes connexes combines avec le taxol
ZA941290B (en) *	1993-02-26	1995-08-25	Res Dev Foundation	Combination cisplatin/tamoxifen therapy for human cancers
AU7000094A (en) *	1993-06-17	1995-01-17	Ciba-Geigy Ag	Indolocarbazole compound useful as proteinkinase c inhibitor

1996
- 1996-06-26 JP JP9504545A patent/JPH11509193A/ja active Pending
- 1996-06-26 AU AU63960/96A patent/AU715527B2/en not_active Ceased
- 1996-06-26 EP EP96923453A patent/EP0835111A2/fr not_active Withdrawn
- 1996-06-26 WO PCT/US1996/010921 patent/WO1997001344A2/fr not_active Ceased
- 1996-06-26 CA CA002225682A patent/CA2225682A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
AU6396096A (en)	1997-01-30
WO1997001344A2 (fr)	1997-01-16
EP0835111A2 (fr)	1998-04-15
AU715527B2 (en)	2000-02-03
CA2225682A1 (fr)	1997-01-16
WO1997001344A3 (fr)	1997-03-27

Publication	Publication Date	Title
Vendetti et al.	2015	The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo
Bruce et al.	1966	Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo
KR102473113B1 (ko)	2022-12-01	암 치료를 위한 병용 요법
Naus et al.	2007	Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways
Magnussen et al.	2015	Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
Robey et al.	2007	Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure
US20240350481A1 (en)	2024-10-24	Use of n-myristoyl transferase (nmt) inhibitors in the treatment of cancer, autoimmune disorders, and inflammatory disorders
JPH10512277A (ja)	1998-11-24	タンパク質キナーゼ阻害剤を含有する癌細胞における多剤耐性を予防するための化合物
Matsui et al.	1996	DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells
Archie et al.	2009	90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1
Sexauer et al.	2023	DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia
US11241442B2 (en)	2022-02-08	Methods of use for TRP channel antagonist-based combination cancer therapies
US6274576B1 (en)	2001-08-14	Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
Krishna et al.	2009	Cytotoxic studies of anti-neoplastic drugs on human lymphocytes–In vitro studies
Ma et al.	2023	Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia
Havas et al.	2024	Defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma
Sarek et al.	2013	Kaposi's sarcoma herpesvirus lytic replication compromises apoptotic response to p53 reactivation in virus-induced lymphomas
JPH11509193A (ja)	1999-08-17	細胞傷害を増強するための細胞周期動力学の動的遅延方法
Modi et al.	2017	Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells
US20220151976A1 (en)	2022-05-19	Targeting lasp1, eif4a1, eif4b and cxc4 with modulators and combinations thereof for cancer therapy
Gabai et al.	2008	Triggering senescence programs suppresses Chk1 kinase and sensitizes cells to genotoxic stresses
UA109571C2 (uk)	2015-09-10	Спосіб лікування раку кровотворної системи із застосуванням фородезину в комбінації з бендамустином, а також фармацевтична композиція та комплект, що їх містять
US20210369681A1 (en)	2021-12-02	Identification of PPM1D mutations as a novel biomarker for NAMPTi sensitivity
Rosier et al.	2004	Role of 2′-2′ difluorodeoxycytidine (gemcitabine)-induced cell cycle dysregulation in radio-enhancement of human head and neck squamous cell carcinomas
Marashdeh et al.	2025	Synergistic antileukemic effects of hydroxyurea and SRJ23 in T-cell acute lymphoblastic leukemia